Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials

• Main Authors: Rui Sun (Author), Mercedes Bustamante (Author), Venkatesh Kumar Gurusamy (Author), Mark Lebwohl (Author), Alice B. Gottlieb (Author), Philip J. Mease (Author), Atul Deodhar (Author), Weibin Bao (Author), Meryl Mendelson (Author), Brian Porter (Author), Deepa Chand (Author), Victor Dong (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Secukinumab is an anti-interleukin (IL)-17A monoclonal antibody indicated for multiple immunological disorders. Here, we aim to summarize secukinumab safety in clinical trials (CTs) and post-marketing setting (PMS) until 25 June 2022. Methods Adverse events (AEs) were summarize...